AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy most frequently involving the nasal cavity and upper aerodigestive tract, although it may present in other extranodal ...

For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study ...

Granulocyte colony-stimulating factor to be started on day 6. Cycles to be repeated every 28 days. SMILE: Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide. Stage I/II ...

The first clinical program to go over involves the use of ImmunityBio's CAR-NK cell therapy CD19 t-haNK, which is being tested in the ongoing phase 1 QUILT 106 study. As I alluded to above, the stock ...